$CLRB
Cellectar Biosciences, Inc.

2023 Q4 Form 10-Q Financial Statement

#000141057823002341 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.611M $2.100M
YoY Change 134.23% -13.77%
% of Gross Profit
Research & Development $7.936M $7.313M
YoY Change 45.52% 35.92%
% of Gross Profit
Depreciation & Amortization $72.38K $40.00K
YoY Change 89.68% 21.36%
% of Gross Profit
Operating Expenses $12.55M $7.313M
YoY Change 69.05% 35.92%
Operating Profit -$9.413M
YoY Change 20.45%
Interest Expense $5.039M $51.11K
YoY Change 3317.81% 1127.43%
% of Operating Profit
Other Income/Expense, Net -$4.319M
YoY Change -103819.74%
Pretax Income -$7.509M -$13.73M
YoY Change 3.21% 75.77%
Income Tax -$60.00K
% Of Pretax Income
Net Earnings -$7.449M -$13.73M
YoY Change 3.24% 75.8%
Net Earnings / Revenue
Basic Earnings Per Share -$1.21
Diluted Earnings Per Share -$0.49 -$1.21
COMMON SHARES
Basic Shares Outstanding 12.29M 9.741M
Diluted Shares Outstanding 11.31M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.565M $18.99M
YoY Change -51.85% 6.77%
Cash & Equivalents $9.565M $18.99M
Short-Term Investments
Other Short-Term Assets $888.2K $1.120M
YoY Change 33.92% 14.76%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $10.45M $20.11M
YoY Change -49.08% 7.19%
LONG-TERM ASSETS
Property, Plant & Equipment $1.593M $893.5K
YoY Change 280.42% 163.62%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $29.78K $6.214K
YoY Change 379.24% -92.35%
Total Long-Term Assets $1.622M $1.441M
YoY Change 53.03% 158.1%
TOTAL ASSETS
Total Short-Term Assets $10.45M $20.11M
Total Long-Term Assets $1.622M $1.441M
Total Assets $12.08M $21.55M
YoY Change -44.07% 11.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.179M $7.810M
YoY Change 258.82% 22.66%
Accrued Expenses $58.98K $60.00K
YoY Change 15.99% -59.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.94M $16.47M
YoY Change 133.98% 152.81%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $494.0K $510.0K
YoY Change -10.67% 848.48%
Total Long-Term Liabilities $494.0K $510.0K
YoY Change -10.67% 848.48%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.94M $16.47M
Total Long-Term Liabilities $494.0K $510.0K
Total Liabilities $13.43M $16.98M
YoY Change 120.83% 158.54%
SHAREHOLDERS EQUITY
Retained Earnings -$217.5M -$210.0M
YoY Change 21.16% 21.91%
Common Stock $207.00 $99.00
YoY Change 120.21% 62.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.356M -$13.35M
YoY Change
Total Liabilities & Shareholders Equity $12.08M $21.55M
YoY Change -44.07% 11.55%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$7.449M -$13.73M
YoY Change 3.24% 75.8%
Depreciation, Depletion And Amortization $72.38K $40.00K
YoY Change 89.68% 21.36%
Cash From Operating Activities -$9.597M -$8.070M
YoY Change 29.48% 15.07%
INVESTING ACTIVITIES
Capital Expenditures $264.0K $600.0K
YoY Change 124.05% -8586.56%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$264.0K -$600.0K
YoY Change 124.05% 8386.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 439.6K 22.50M
YoY Change -95.43%
NET CHANGE
Cash From Operating Activities -9.597M -8.070M
Cash From Investing Activities -264.0K -600.0K
Cash From Financing Activities 439.6K 22.50M
Net Change In Cash -9.421M 13.83M
YoY Change -552.72% -297.0%
FREE CASH FLOW
Cash From Operating Activities -$9.597M -$8.070M
Capital Expenditures $264.0K $600.0K
Free Cash Flow -$9.861M -$8.670M
YoY Change 30.96% 23.75%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Central Index Key
EntityCentralIndexKey
0001279704
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
111
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
111
CY2022Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.10
CY2022Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.10
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9918384
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9385272
CY2023Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P60M
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
1-36598
dei Entity Registrant Name
EntityRegistrantName
CELLECTAR BIOSCIENCES, INC.
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3321804
dei Entity Address Address Line1
EntityAddressAddressLine1
100 Campus Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Florham Park
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07932
dei City Area Code
CityAreaCode
608
dei Local Phone Number
LocalPhoneNumber
441-8120
dei Security12b Title
Security12bTitle
Common stock, par value $0.00001
dei Trading Symbol
TradingSymbol
CLRB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12288325
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18986443
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19866358
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1123467
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
663243
CY2023Q3 us-gaap Assets Current
AssetsCurrent
20109910
CY2022Q4 us-gaap Assets Current
AssetsCurrent
20529601
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
893509
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
418641
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
517566
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
560334
CY2023Q3 us-gaap Long Term Investments
LongTermInvestments
23566
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
75000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6214
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6214
CY2023Q3 us-gaap Assets
Assets
21550765
CY2022Q4 us-gaap Assets
Assets
21589790
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7814590
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5478443
CY2023Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
8600000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
56263
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
50847
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
16470853
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5529290
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
512750
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
552981
CY2023Q3 us-gaap Liabilities
Liabilities
16983603
CY2022Q4 us-gaap Liabilities
Liabilities
6082271
CY2023Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.00001
CY2023Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
7000
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
7000
CY2023Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
1225
CY2023Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
1225
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2023Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
17920000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
111
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
111
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
1382023
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
1382023
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9918384
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9385272
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
99
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
94
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
195298922
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
193624445
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-210033882
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-179499043
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-13352838
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15507519
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21550765
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21589790
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7312504
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5380190
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20275004
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13765846
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2100956
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2435296
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6137760
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7625391
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
9413460
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
7815486
us-gaap Costs And Expenses
CostsAndExpenses
26412764
us-gaap Costs And Expenses
CostsAndExpenses
21391237
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9413460
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7815486
us-gaap Operating Income Loss
OperatingIncomeLoss
-26412764
us-gaap Operating Income Loss
OperatingIncomeLoss
-21391237
CY2023Q3 clrb Warrant Issuance Expense From Nonoperating
WarrantIssuanceExpenseFromNonoperating
470000
clrb Warrant Issuance Expense From Nonoperating
WarrantIssuanceExpenseFromNonoperating
470000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3900000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3900000
us-gaap Payments For Rent
PaymentsForRent
11800
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
51110
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4164
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
247925
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
5075
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4318890
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4164
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4122075
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5075
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-13732350
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7811322
us-gaap Net Income Loss
NetIncomeLoss
-30534839
us-gaap Net Income Loss
NetIncomeLoss
-21386162
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.21
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.21
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.28
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.28
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.71
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.71
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.50
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.50
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11308738
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11308738
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6110119
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6110119
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11277231
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11277231
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6110123
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6110123
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
33045154
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
303805
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-6139797
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
27209162
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
419953
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7435043
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
20194072
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
367759
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7811322
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
12750509
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15507519
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
408206
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
3
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-8581267
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
7334461
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
419757
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8221222
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-467004
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
497878
CY2023Q3 clrb Exercise Of Warrants Into Common Shares Value
ExerciseOfWarrantsIntoCommonSharesValue
348638
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
29540110
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-13732350
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-13352838
us-gaap Net Income Loss
NetIncomeLoss
-30534839
us-gaap Net Income Loss
NetIncomeLoss
-21386162
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
122415
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
110276
us-gaap Share Based Compensation
ShareBasedCompensation
1325841
us-gaap Share Based Compensation
ShareBasedCompensation
1091517
clrb Non Cash Lease Expense
NonCashLeaseExpense
42768
clrb Non Cash Lease Expense
NonCashLeaseExpense
66547
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-3386
clrb Warrant Issuance Expense Operating Activities
WarrantIssuanceExpenseOperatingActivities
470000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3900000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
408790
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
108451
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-34815
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-99772
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2336146
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2512121
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22781274
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17810538
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
597282
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
108115
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-597282
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-108115
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
348641
clrb Proceeds From Issuance Of Preferred Stock And Warrants Net Of Issuance Cost
ProceedsFromIssuanceOfPreferredStockAndWarrantsNetOfIssuanceCost
-22150000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22498641
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-879915
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17918653
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19866358
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35703975
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18986443
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17785322
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-210034000
us-gaap Net Income Loss
NetIncomeLoss
-30535000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span> — The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Significant estimates include the assumptions used in the accrual for potential liabilities, the valuation of the warrant liability, the valuation of debt and equity instruments, the valuation of stock options issued for services, and deferred tax valuation allowances. Actual results could differ from those estimates.</p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2328755
clrb Increase In Percentage Of Rent
IncreaseInPercentageOfRent
0.02
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.14
CY2018Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span> — Financial instruments that subject the Company to credit risk consist of cash and cash equivalents on deposit with financial institutions. The Company’s excess cash as of September 30, 2023 and December 31, 2022 is on deposit in interest-bearing accounts with well-established financial institutions. At times, such amounts may exceed the FDIC insurance limits. As of September 30, 2023, and December 31, 2022, uninsured cash balances totaled approximately $18,486,000 and $19,400,000, respectively.</p>
CY2023Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
18486000
CY2022Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
19400000
clrb Class Of Warrant Or Right Number Of Warrants Exercised
ClassOfWarrantOrRightNumberOfWarrantsExercised
177877
CY2023Q3 clrb Class Of Warrant Or Right Number Of Warrants Exercised
ClassOfWarrantOrRightNumberOfWarrantsExercised
177877
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
348638
CY2023Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
348638
CY2023Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
28668953
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1542000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
340250
CY2023Q3 us-gaap Area Of Land
AreaOfLand
3983
CY2023Q3 us-gaap Lease Deposit Liability
LeaseDepositLiability
23566
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
35000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
132000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
147000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
150000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
153000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
207000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
824000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
255000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
569000

Files In Submission

Name View Source Status
clrb-20230930_cal.xml Edgar Link unprocessable
0001410578-23-002341-index-headers.html Edgar Link pending
0001410578-23-002341-index.html Edgar Link pending
0001410578-23-002341.txt Edgar Link pending
0001410578-23-002341-xbrl.zip Edgar Link pending
clrb-20230930.xsd Edgar Link pending
clrb-20230930x10q.htm Edgar Link pending
clrb-20230930xex31d1.htm Edgar Link pending
clrb-20230930xex31d2.htm Edgar Link pending
clrb-20230930xex32d1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
clrb-20230930_def.xml Edgar Link unprocessable
clrb-20230930_lab.xml Edgar Link unprocessable
clrb-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
clrb-20230930x10q_htm.xml Edgar Link completed
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending